This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Wu, J.-Y. Articles by Yang, P.-C. PubMed PubMed Citation Articles by Wu, J.-Y. Articles by Yang, P.-C.

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Authors' Affiliation: Departments of ¹ Internal Medicine, ² Oncology, and ³ Pathology, National Taiwan University Hospital, Taipei, Taiwan, and ⁴ Division of Critical Care Medicine, Department of Emergency and Critical Care Medicine, Lo-Tung Poh-Ai Hospital, Yi-Lan, Taiwan

Requests for reprints: Jin-Yuan Shih, Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, Taiwan. Phone: 886-2-23562905; Fax: 886-2-23582867; E-mail: jyshih{at}ntu.edu.tw.

Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib, we investigated the clinical features of lung cancer in patients with exon 20 mutations and analyzed the gefitinib treatment response.

Experimental Design: We surveyed the clinical data and mutational studies of NSCLC patients with EGFR exon 20 mutations in the National Taiwan University Hospital and reviewed the literature reports about EGFR exon 20 mutations and the gefitinib treatment response.

Results: Twenty-three patients with mutations in exon 20 were identified. Nine (39%) had coexisting mutations in EGFR exons other than exon 20. Sixteen patients received gefitinib treatment, and a response was noted in 4 patients. The gefitinib response rate of NSCLC with exon 20 mutations was 25%, far lower than those with deletions in exon 19 and L858R mutations. Interestingly, different exon 20 mutations and coexisting mutations seemed to have a different influence on gefitinib response.

Conclusions: EGFR exon 20 mutations of NSCLC patients result in poorer responsiveness to gefitinib treatment, but variability exists between different individuals.

This article has been cited by other articles:

				J.-Y. Wu, C.-J. Yu, C.-H. Yang, S.-G. Wu, Y.-H. Chiu, C.-H. Gow, Y.-C. Chang, Y.-C. Hsu, P.-F. Wei, J.-Y. Shih, et al. First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 847 - 853. [Abstract] [Full Text] [PDF]